Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: FHTX

Foghorn Therapeutics Inc.

Healthcare | Biotechnology

Market prices for FHTX are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.99

Foghorn Therapeutics Inc. (NASDAQ: FHTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:03 UTC.

What Foghorn Therapeutics Inc. does

Foghorn is a clinical-stage biotechnology company developing precision medicines that target the chromatin regulatory system, which controls gene expression and is implicated in cancer and other diseases. The company has built a proprietary Gene Traffic Control platform that enables the identification, validation, and development of drugs against chromatin regulatory targets through capabilities including genomic screening, production of chromatin components at scale, and high-throughput screening technology.

Summarized from Foghorn Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.99

Revenue, margins & earnings

FY2021: net loss $101M on revenue $1M$1MFY2021FY2022: net loss $109M on revenue $19M$19MFY2022FY2023: net loss $98M on revenue $34M$34MFY2023FY2024: net loss $87M on revenue $23M$23MFY2024FY2025: net loss $74M on revenue $31M$31MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-25
Most recent filed transactions — June 2026:
  • 2026-06-25DirectorStock Options (Right to buy)Award28,000$114.2K
  • 2026-06-25DirectorStock Options (Right to buy)Award28,000$114.2K
  • 2026-06-25DirectorStock Options (Right to buy)Award28,000$114.2K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Foghorn Therapeutics Inc. do?

Foghorn is a clinical-stage biotechnology company developing precision medicines that target the chromatin regulatory system, which controls gene expression and is implicated in cancer and other diseases.

When did FHTX last file with the SEC?

Foghorn Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-24. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:03 UTC. This page is also available as JSON at /api/data?ticker=FHTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for FHTX and 5,000+ tickers.

Create a free account — keep FHTX
For your agent
GET /api/data?ticker=FHTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt